EIB funds Ebola vaccine development

Published: 20-Jan-2015
Research & Development Infection Control

Lends Bavarian Nordic €50m to accelerate Ebola project


The European Investment Bank (EIB) is lending €50m to Denmark-based biotechnology company Bavarian Nordic to accelerate its work in developing a vaccine against the Ebola virus. The decision showed that the bank backed 'investment where it is needed…in difficult or uncertain circumstances', claimed EIB President Werner Hoyer. The company started Phase 1 clinical trials this month.

See more

You may also like

Research & Development

EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines

Read more
Prostvac is the company's leading targeted immunotherapy candidate

Trending Articles

  1. Xybion launches AI-enabled LIMS technology, LIMS 10.0 The laboratory information management system (LIMS) can improve a lab's functionality and efficiency for users across a vast range of industries
  2. AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
  3. Nulogy and OMP expand supply chain solution partnership The companies are expanding their partnership, offering their combined solutions and services to additional industries to fulfil their growing need for digital transformation of internal planning and external supplier network collaboration
  4. Hovione and Zerion Pharma create joint venture to further expand the use of Dispersome technology Hovione Farmaciência and Zerion Pharma have expanded their partnership to accelerate the development of the Dispersome technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules
  5. SRI International awarded US$19.8m National Cancer Institute contract for PREVENT Cancer programme Will conduct preclinical studies to assess the efficacy of specific compounds or vaccines for preventing invasive-cancer development

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

You may also like

Research & Development

EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines

Prostvac is the company's leading targeted immunotherapy candidate
Research & Development

Xybion launches AI-enabled LIMS technology, LIMS 10.0

The laboratory information management system (LIMS) can improve a lab's functionality and efficiency for users across a vast range of industries
Research & Development

AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial

The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
Research & Development

Hovione and Zerion Pharma create joint venture to further expand the use of Dispersome technology

Hovione Farmaciência and Zerion Pharma have expanded their partnership to accelerate the development of the Dispersome technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules
Research & Development

Sterling Pharma Solutions announces partnership with Soligenix to manufacture oncology-targeted API

Sterling Pharma Solutions and Soligenix have announced a partnership that will see Sterling manufacture a GMP-quality synthetic hypericin developed by Soligenix for its oncology drug, HyBryte, in clinical trials
Manufacturing

Olon strengthens market position with acquisitions ahead of CPHI Milan

Two new acquisitions expand Olon’s service offerings and production capacity
Research & Development

Almac Group announces £11m investment to expand global analytical services

The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities
Subscribe now